Is DNA a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on AI, autonomous labs, and Datapoints, with revenue (ttm) at ~$132 million, with Q2 2026 revenue of ~$20 million down ~48% year over year. The bear case rests on the dominant risk is cash burn against an uncertain path to profitability: Ginkgo remains deeply unprofitable, revenue has kept falling year over year (Q2 2026 revenue was down about 48%), and it is spending down its cash (about $302 million at June 30, 2026, against about $404 million of debt including leases) while promising breakeven that has not yet arrived. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The dominant risk is cash burn against an uncertain path to profitability: Ginkgo remains deeply unprofitable, revenue has kept falling year over year (Q2 2026 revenue was down about 48%), and it is spending down its cash (about $302 million at June 30, 2026, against about $404 million of debt including leases) while promising breakeven that has not yet arrived. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. Walnut is not an investment adviser.

AI, autonomous labs, and Datapoints. Ginkgo's central bet is that AI-driven, robot-run autonomous labs will replace the traditional lab bench.

The dominant risk is cash burn against an uncertain path to profitability: Ginkgo remains deeply unprofitable, revenue has kept falling year over year (Q2 2026 revenue was down about 48%), and it is spending down its cash (about $302 million at June 30, 2026, against about $404 million of debt including leases) while promising breakeven that has not yet arrived. If losses persist, further capital raises could dilute existing shareholders, and the company already completed a 1-for-40 reverse split after its post-SPAC valuation collapsed by billions, a reminder of how far expectations have reset. Customer concentration is a concern because a handful of large partners can drive results, and losing or delaying programs hits revenue hard. Competition spans synthetic-biology, lab-automation, and bio-AI players with more focus or funding. Execution risk on the autonomous-lab pivot is high, and the stock is speculative and volatile, so outcomes could be very good or very poor. Wall Street coverage is thin and skeptical: the two analysts in the Yahoo Finance consensus rate it underperform with a mean target near $8, below the October 16 close of $10.53.

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (AI, autonomous labs, and Datapoints) stalling in the reported numbers rather than in the narrative, the risk above (the dominant risk is cash burn against an uncertain path to profitability: Ginkgo remains deeply unprofitable, revenue has kept falling year over year (Q2 2026 revenue was down about 48%), and it is spending down its cash (about $302 million at June 30, 2026, against about $404 million of debt including leases) while promising breakeven that has not yet arrived) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

That depends on your goals, time horizon, and risk tolerance, and this is not investment advice. Ginkgo is a speculative, unprofitable company with falling revenue and ongoing cash burn, so it is high-risk. The bull case is that its autonomous-lab and Datapoints pivot scales into a profitable business after deep cost cuts; the bear case is continued losses, dilution, and a thesis that never pays off. Weigh both against your portfolio.

Ginkgo runs a horizontal cell-programming platform: it uses automated labs, software, and biological data to engineer and characterize cells for pharma, agriculture, food, and industrial customers. It earns money from R&D service fees, its Datapoints data-generation service, and its lab-automation systems. After selling its Biosecurity unit in 2026, it is focused on Cell Engineering and autonomous labs.

No. Ginkgo is unprofitable and has reported large net losses, and its revenue has been shrinking year over year. Since 2024 it has cut costs aggressively and targets adjusted-EBITDA breakeven by the end of 2026, but that is an adjusted measure and does not mean GAAP profitability. Anyone considering the stock should treat it as a pre-profit, cash-burning company. Over the twelve months to June 2026 it lost about $310 million on about $132 million of revenue.